Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban.

Rivaroxaban and apixaban are effective oral anticoagulants, but their usage has been associated with an increased risk of bleeding events. This study examined the bleeding and thromboembolic events of rivaroxaban and apixaban. Medical records from 114 patients (rivaroxaban = 64, apixaban = 80) treated for stroke prevention in atrial fibrillation at a tertiary hospital in Malaysia were retrospectively reviewed.